{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:37:46Z","timestamp":1767008266053,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41391-017-0031-8","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T16:22:07Z","timestamp":1513959727000},"page":"373-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-8693","authenticated-orcid":false,"given":"Ville","family":"Kukko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Kaipia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Taari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L. J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teemu J.","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"31_CR1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrurol.2015.301","volume":"13","author":"L Vignozzi","year":"2016","unstructured":"Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108\u201319.","journal-title":"Nat Rev Urol"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.pcan.4500221","volume":"1","author":"J Hammarsten","year":"1998","unstructured":"Hammarsten J, H\u00f6gstedt B, Holthuis N, Mellstr\u00f6m D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157\u201362.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"31_CR3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrurol.2016.168","volume":"13","author":"C Nunzio De","year":"2016","unstructured":"De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13:613\u201326.","journal-title":"Nat Rev Urol"},{"key":"31_CR4","doi-asserted-by":"crossref","unstructured":"Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res. 2016. [cited 14 Sep 2017];35. Available at http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5017015\/.","DOI":"10.1186\/s13046-016-0418-8"},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/pros.23100","volume":"76","author":"P Vital","year":"2016","unstructured":"Vital P, Castro P, Ittmann M. Oxidative stress promotes benign prostatic hyperplasia. Prostate. 2016;76:58\u201367.","journal-title":"Prostate"},{"key":"31_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11010-016-2671-8","volume":"414","author":"F Sangkop","year":"2016","unstructured":"Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem. 2016;414:187\u201399.","journal-title":"Mol Cell Biochem"},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrurol.2012.192","volume":"10","author":"DD \u00d8rsted","year":"2013","unstructured":"\u00d8rsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49\u201354.","journal-title":"Nat Rev Urol"},{"key":"31_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/03009742.2013.878387","volume":"43","author":"CJ Chen","year":"2014","unstructured":"Chen C-J, Yen J-H, Chang S-J. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014;43:385\u201390.","journal-title":"Scand J Rheumatol"},{"key":"31_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0960327109105406","volume":"28","author":"GD Castro","year":"2009","unstructured":"Castro GD, Costantini MH, Castro JA. Rat ventral prostate xanthine oxidase-mediated metabolism of acetaldehyde to acetyl radical. Hum Exp Toxicol. 2009;28:203\u20138.","journal-title":"Hum Exp Toxicol"},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10715769809065801","volume":"28","author":"Z Zhang","year":"1998","unstructured":"Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, et al. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res. 1998;28:151\u201364.","journal-title":"Free Radic Res"},{"key":"31_CR11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/VHRM.S115080","volume":"13","author":"M Bove","year":"2017","unstructured":"Bove M, Cicero AFG, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag. 2017;13:23\u20138.","journal-title":"Vasc Health Risk Manag"},{"key":"31_CR12","first-page":"35","volume":"147","author":"F Pea","year":"2005","unstructured":"Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35\u201346.","journal-title":"Contrib Nephrol"},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prnil.2015.08.001","volume":"4","author":"D Parikesit","year":"2016","unstructured":"Parikesit D, Mochtar CA, Umbas R, Hamid ARAH. The impact of obesity towards prostate diseases. Prostate Int. 2016;4:1\u20136.","journal-title":"Prostate Int"},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djt038","volume":"105","author":"TP Kilpel\u00e4inen","year":"2013","unstructured":"Kilpel\u00e4inen TP, Tammela TL, Malila N, Hakama M, Santti H, M\u00e4\u00e4tt\u00e4nen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105:719\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"31_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/21681805.2016.1145734","volume":"50","author":"S Sarre","year":"2016","unstructured":"Sarre S, M\u00e4\u00e4tt\u00e4nen L, Tammela TLJ, Auvinen A, Murtola TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scand J Urol. 2016;50:267\u201373.","journal-title":"Scand J Urol"},{"key":"31_CR16","unstructured":"WHOCC - ATC\/DDD Index. [cited 14 Sep 2017]. Available at https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/pros.23020","volume":"75","author":"T Veitonm\u00e4ki","year":"2015","unstructured":"Veitonm\u00e4ki T, Murtola TJ, M\u00e4\u00e4tt\u00e4nen L, Taari K, Stenman U-H, Tammela TLJ, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. Prostate. 2015;75:1394\u2013402.","journal-title":"Prostate"},{"key":"31_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-42542-9_8","volume":"208","author":"Y Cao","year":"2016","unstructured":"Cao Y, Giovannucci E. Obesity and Prostate Cancer. Recent Results Cancer Res. 2016;208:137\u201353.","journal-title":"Recent Results Cancer Res"},{"key":"31_CR19","doi-asserted-by":"crossref","unstructured":"Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, et al. Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. The article is in press. Therefore: Hellenic J Cardiol 2017 (in press)","DOI":"10.1016\/j.hjc.2017.01.004"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10787-017-0314-7","volume":"25","author":"MS Ellulu","year":"2017","unstructured":"Ellulu MS. Obesity, cardiovascular disease, and role of vitamin C on inflammation: a review of facts and underlying mechanisms. Inflammopharmacology. 2017;25:313\u201328.","journal-title":"Inflammopharmacology"},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.2174\/138161205774913255","volume":"11","author":"GK Glantzounis","year":"2005","unstructured":"Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005;11:4145\u201351.","journal-title":"Curr Pharm Des"},{"key":"31_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4149\/neo_2015_015","volume":"62","author":"K Szewczyk-Golec","year":"2015","unstructured":"Szewczyk-Golec K, Tyloch J, Czuczejko J. Antioxidant defense system in prostate adenocarcinoma and benign prostate hyperplasia of elderly patients. Neoplasma. 2015;62:119\u201323.","journal-title":"Neoplasma"},{"key":"31_CR23","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/ijms15023118","volume":"15","author":"AI Rup\u00e9rez","year":"2014","unstructured":"Rup\u00e9rez AI, Gil A, Aguilera CM. Genetics of oxidative stress in obesity. Int J Mol Sci. 2014;15:3118\u201344.","journal-title":"Int J Mol Sci"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0031-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0031-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-017-0031-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:03Z","timestamp":1684618383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-017-0031-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1038\/s41391-017-0031-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"type":"print","value":"1365-7852"},{"type":"electronic","value":"1476-5608"}],"subject":[],"published":{"date-parts":[[2017,12,22]]}}}